Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A long-acting somatostatin analog FDA-approved for acromegaly and gastroenteropancreatic neuroendocrine tumors. Administered as a deep subcutaneous depot injection once monthly.
A synthetic octapeptide analog of somatostatin with a much longer half-life than the natural hormone. FDA-approved for acromegaly, carcinoid tumors, and VIPomas. One of the foundational peptide drugs in endocrinology.
Binds primarily to somatostatin receptor subtypes 2 and 5 (SSTR2, SSTR5), inhibiting growth hormone secretion, reducing IGF-1 levels, and suppressing tumor growth in neuroendocrine tumors.
Binds to somatostatin receptors (primarily SSTR2 and SSTR5), inhibiting growth hormone, glucagon, and insulin secretion. Reduces splanchnic blood flow and inhibits GI motility and secretion.
- Acromegaly
- Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
- Carcinoid syndrome
- Acromegaly
- Carcinoid syndrome
- VIPomas
- GI bleeding (variceal)
- Dumping syndrome
- GI side effects (diarrhea, abdominal pain)
- Gallstones
- Injection site reactions
- Hyperglycemia
- Bradycardia
- Gallstones (common with long-term use)
- GI side effects (diarrhea, nausea)
- Hyperglycemia or hypoglycemia
- Injection site pain
- Bradycardia
FDA-approved as Somatuline Depot (2007) for acromegaly and GEP-NETs. Administered as a deep subcutaneous injection in the gluteal region once every 4 weeks.
FDA-approved as Sandostatin (1988, subcutaneous) and Sandostatin LAR (1998, monthly depot). Generic octreotide available. Widely used in endocrinology and oncology.
- Octreotide in the treatment of acromegaly
1990 · PubMed
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.